Polymorphisms in the endocannabinoid receptor 1 in relation to fat mass distribution

European Journal of Endocrinology

Volumn 163, Issue 3, 2010, Pages 407-412

  Frost, M ^a   Nielsen, T L ^a   Wraae, K ^a   Hagen, C ^b   Piters, E ^c   Beckers, S ^c   De Freitas, F ^c   Brixen, K ^a   Van Hul, W ^c   Andersen, M ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b BISPEBJERG HOSPITAL   (Denmark)

^c UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID 1 RECEPTOR; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY FAT; BODY FAT DISTRIBUTION; CHOLESTEROL BLOOD LEVEL; DUAL ENERGY X RAY ABSORPTIOMETRY; GENETIC VARIABILITY; GENOTYPE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPOSE TISSUE; ADULT; BODY FAT DISTRIBUTION; ENDOCANNABINOIDS; FOLLOW-UP STUDIES; GENETIC VARIATION; HUMANS; LINKAGE (GENETICS); MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, CANNABINOID, CB1; YOUNG ADULT;

EID: 77956270559     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-10-0192     Document Type: Article

References (23)

1. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R & Pertwee RG. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacological Reviews 2002 54 161-202. (doi:10.1124/pr.54.2.161)
2. Matias I & Di Marzo V. Endocannabinoids and the control of energy balance. Trends in Endocrinology and Metabolism 2007 18 27-37. (doi:10.1016/j.tem.2006.11.006)
3. Eckardt K, Sell H, Taube A, Koenen M, Platzbecker B, Cramer A, Horrighs A, Lehtonen M, Tennagels N & Eckel J. Cannabinoid type 1 receptors in human skeletal muscle cells participate in the negative crosstalk between fat and muscle. Diabetologia 2009 52 664-674. (doi:10.1007/s00125-008-1240-4)
4. Van Gaal LF, Scheen AJ, Rissanen AM, Rossner S, Hanotin C & Ziegler O. Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study. European Heart Journal 2008 29 1761-1771. (doi:10.1093/eurheartj/ehn076)
5. Despres JP, Golay A & Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. New England Journal of Medicine 2005 353 2121-2134. (doi:10.1056/NEJMoa044537)
6. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J & Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. Journal of the American Medical Association 2006 295 761-775. (doi:10.1001/jama.295.7.761)
7. Scheen AJ, Finer N, Hollander P, Jensen MD & Van Gaal LF. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006 368 1660-1672. (doi:10.1016/S0140-6736(06)69571-8)
8. Di Marzo V, Goparaju SK, Wang L, Liu J, Bátkai S, Járai Z, Fezza F, Miura GI, Palmiter RD, Sugiura T & Kunos G. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001 410 822-825. (doi:10.1038/35071088)
9. Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Bátkai S, Harvey-White J, Mackie K, Offertáler L, Wang L & Kunos G. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. Journal of Clinical Investigation 2005 115 1298-1305. (doi:10.1172/JCI23057)
10. Peeters A, Beckers S, Mertens I, Van Hul W & Van Gaal L. The G1422A variant of the cannabinoid receptor gene (CNR1) is associated with abdominal adiposity in obese men. Endocrine 2007 31 138-141. (doi:10.1007/s12020-007-0022- y)
11. Gazzerro P, Caruso MG, Notarnicola M, Misciagna G, Guerra V, Laezza C & Bifulco M. Association between cannabinoid type-1 receptor polymorphism and body mass index in a Southern Italian population. International Journal of Obesity 2007 31 908-912. (doi:10.1038/sj.ijo.0803510)
12. Müller TD, Reichwald K, Wermter AK, Brönner G, Nguyen TT, Friedel S, Koberwitz K, Engeli S, Lichtner P, Meitinger T, Schäfer H, Hebebrand J & Hinney A. No evidence for an involvement of variants in the cannabinoid receptor gene (CNR1) in obesity in German children and adolescents. Molecular Genetics and Metabolism 2007 90 429-434. (doi:10.1016/j.ymgme.2007.01. 002)
13. LiebW, Manning AK, Florez JC, Dupuis J, Cupples LA, McAteer JB, Vasan RS, Hoffmann U, O'Donnell CJ, Meigs JB & Fox CS. Variants in the CNR1 and the FAAH genes and adiposity traits in the community. Obesity 2009 17 755-760. (doi:10.1038/oby.2008.608)
14. Benzinou M, Chèvre JC, Ward KJ, Lecoeur C, Dina C, Lobbens S, Durand E, Delplanque J, Horber FF, Heude B, Balkau B, Borch-Johnsen K, Jørgensen T, Hansen T, Pedersen O, Meyre D & Froguel P. Endocannabinoid receptor 1 gene variations increase risk for obesity and modulate body mass index in European populations. Human Molecular Genetics 2008 17 1916-1921. (doi:10.1093/hmg/ddn089)
15. Nielsen TL, Wraae K, Brixen K, Hermann AP, Andersen M & Hagen C. Prevalence of overweight, obesity and physical inactivity in 20- to 29-year-old, Danish men. Relation to sociodemography, physical dysfunction and low socioeconomic status: the Odense Androgen Study. International Journal of Obesity 2006 30 805-815. (doi:10.1038/sj.ijo.0803197)
16. Nielsen TL, Hagen C, Wraae K, Brixen K, Petersen PH, Haug E, Larsen R & Andersen M. Visceral and subcutaneous adipose tissue assessed by magnetic resonance imaging in relation to circulating androgens, sex hormone-binding globulin, and luteinizing hormone in young men. Journal of Clinical Endocrinology and Metabolism 2007 92 2696-2705. (doi:10.1210/jc.2006-1847)
17. Altman DG. Practical Statistics for Medical Research, 1991 London: Chapman & Hall.
18. Volgyi E, Tylavsky FA, Lyytikainen A, Suominen H, Alen M & Cheng S. Assessing body composition with DXA and bioimpedance: effects of obesity, physical activity, and age. Obesity 2008 16 700-705. (doi:10.1038/oby.2007.94) (Pubitemid 351328023)
19. Gallagher D, Kuznia P, Heshka S, Albu J, Heymsfield SB, Goodpaster B, Visser M & Harris TB. Adipose tissue in muscle: a novel depot similar in size to visceral adipose tissue. American Journal of Clinical Nutrition 2005 81 903-910. (Pubitemid 41725001)
20. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocrine Reviews 2000 21 697-738. (doi:10.1210/er.21.6.697)
21. Fox CS, Massaro JM, Hoffmann U, Pou KM, Maurovich-Horvat P, Liu CY, Vasan RS,Murabito JM,Meigs JB, Cupples LA, D'Agostino RB Sr & O'Donnell CJ. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 2007 116 39-48. (doi:10.1161/CIRCULATIONAHA.106.675355) (Pubitemid 47016245)
22. Yim JE, Heshka S, Albu JB, Heymsfield S & Gallagher D. Femoral-gluteal subcutaneous and intermuscular adipose tissues have independent and opposing relationships with CVD risk. Journal of Applied Physiology 2008 104 700-707. (doi:10.1152/japplphysiol.01035.2007) (Pubitemid 351468798)
23. Gallagher D, Kelley DE, Yim JE, Spence N, Albu J, Boxt L, Pi-Sunyer FX & Heshka S. Adipose tissue distribution is different in type 2 diabetes. American Journal of Clinical Nutrition 2009 89 807-814. (doi:10.3945/ajcn.2008. 26955)